-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|August 31, 2016

Supplements and Featured Publications

  • In Atopic Dermatitis, Looks Can Be Deceiving

Publishing Staff

Editorial & Production

Senior Vice President of Operationsand Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager

Ida Delmendo

Clinical Projects Manager

Cindy Spielvogel

Project Manager

Jessica Toye

Proofreaders

Griselda Demassey

Maggie Shaw

Associate Editor

Jeanne Linke

Assistant Editor

Sarah Anwar

Clinical Editor

Michael R. Page, PharmD, RPh

Designer

Julianne Costello

Sales & Marketing

Associate Publisher

Justin T. Gallagher

Director of Sales

Sara Belanger

National Account Managers

Gabrielle Consola

Michael Costella

Operations & Finance

Director of Operations

Michael Pico

Vice President of Finance

Leah Babitz, CPA

Accountant

Kim Rotunno

Group Director, Circulation & Production

John Burke

Corporate

Chairman and CEO

Mike Hennessy, Sr

Vice Chairman

Jack Lepping

President

Mike Hennessy, Jr

Chief Financial Officer

Neil Glasser, CPA/CFE

Executive Vice President and General Manager

John Maglione

Chief Marketing Officer

Warren Dardine

Chief Digital Strategy Officer

Steve Ennen

Vice President of Editorial Services and Production

Kerrie Keegan

Vice President, Digital Media

Jung Kim

Chief Creative Officer

Jeff Brown

Human Resource Director

Shari Lundenberg

Articles in this issue

about 10 years ago

Q & A with Dr Silverberg

Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.